This marks a major breakthrough for adolescent girls and young women in high-risk regions such as South Africa and Uganda.
Kintu’s work is deeply personal. Growing up during the peak of Uganda’s HIV epidemic, he witnessed the virus’s devastating toll on families including his own.
These early experiences fuel his commitment to developing innovative prevention methods for underserved populations.
With a PhD from Hárvard and several Gilead research awards, Kintu exemplifies Uganda’s rising influence in global biomedical research. If approved, lenacapavir could transform HIV prevention strategies worldwide.
0 Comments